This is problematic, especially now that the European Medicines Agency (EMA) has only approved durvalumab as consolidation treatment in stage III NSCLC patients whose tumours show PD‐L1 expression of ≥1%.12 Here, CD274 is linked to non-small cell lung carcinoma.